CREDIT AGREEMENT AND GUARANTYCredit Agreement and Guaranty • April 21st, 2020 • ArcherDX, Inc. • In vitro & in vivo diagnostic substances • New York
CREDIT AGREEMENT AND GUARANTY, dated as of May 10, 2019 (this “Agreement”), by and among ArcherDX, Inc., a Delaware corporation (the “Borrower”), certain Subsidiaries of the Borrower from time to time party hereto, Perceptive Credit Holdings II, LP and each other lender that may from time to time become a party hereto (each a “Lender” and collectively, the “Lenders”), and Perceptive Credit Holdings II, LP, as administrative agent for the Lenders (in such capacity, the “Administrative Agent”).
INDUSTRIAL BUILDING LEASEArcherDX, Inc. • April 21st, 2020 • In vitro & in vivo diagnostic substances
Second Amendment to Exclusive Patent License Agreement A217008.05Second Amendment • April 21st, 2020 • ArcherDX, Inc. • In vitro & in vivo diagnostic substances
This Second Amendment (“Second Amendment”) to the Exclusive Patent License Agreement MGH # A217008, (the “Agreement”), dated July 23, 2013 is made as of June 23, 2017 (“Second Amendment Effective Date) by and between The General Hospital Corporation, d/b/a Massachusetts General Hospital, a not-for-profit Massachusetts corporation, with a principal place of business at 55 Fruit Street, Boston, Massachusetts 02114 (“Hospital”) and ArcherDx, Inc., a Delaware Corporation, having a principal place of business at 2477 55th St. # 202 Boulder, Colorado 80301 (“Company”).
AGREEMENT OF SUB-SUBLEASEAgreement of Sub-Sublease • April 21st, 2020 • ArcherDX, Inc. • In vitro & in vivo diagnostic substances • Washington
THIS AGREEMENT OF SUB-SUBLEASE (the “Sublease”) is made this 21st day of November, 2019 (the “Effective Date”), by and between CWB Holdings, Inc., a Colorado corporation (the “Sublandlord”) and ArcherDX, Inc., a Delaware corporation (the “Subtenant”).
AMENDMENT NO. 1 TO SUPPLY AGREEMENTSupply Agreement • April 21st, 2020 • ArcherDX, Inc. • In vitro & in vivo diagnostic substances
This Amendment No. 1 to Supply and Manufacturing Agreement (“Amendment”) is made as of December 20, 2016 and amends certain portions of the Supply and Manufacturing Agreement (the “Agreement”), dated as of December 16, 2014, by and between Qiagen, Inc. (“Qiagen”) and ArcherDx, Inc., (“ArcherDx”).
ARCHERDX, INC. SERVICES AGREEMENTServices Agreement • April 21st, 2020 • ArcherDX, Inc. • In vitro & in vivo diagnostic substances • Delaware
THIS SERVICES AGREEMENT (this “Agreement”) is made and entered into as of April 29, 2019 (the “Effective Date”), by and between ArcherDX, Inc., a Delaware corporation (the “Company”), and Steven Kafka, an individual (the “Executive Chairman”).
SUPPLY AND MANUFACTURING AGREEMENTSupply and Manufacturing Agreement • April 21st, 2020 • ArcherDX, Inc. • In vitro & in vivo diagnostic substances • Massachusetts
As of December 16, 2014 ("Effective Date") between QIAGEN Inc., a California corporation having its principal office at 19300 Germantown Road, Germantown, MD 20874 ("QIAGEN"), and ArcherDX, Inc., a Delaware corporation ("ArcherDX") having its principal office at Flatiron Park West, Building B, 2477 55th Street, Suite 202, Boulder, CO 80301; QIAGEN and ArcherDX also referred to as "Party" and jointly as "Parties".
LICENSE AGREEMENTLicense Agreement • April 21st, 2020 • ArcherDX, Inc. • In vitro & in vivo diagnostic substances • Delaware
This Agreement (this “Agreement”) is made as of the date of the last signature below (the “Effective Date”), by and between Becton, Dickinson and Company, a New Jersey corporation having a place of business at 2350 Qume Drive, San Jose, CA 95131 (“BD”), and ArcherDX, Inc., a Delaware corporation having a place of business at 2477 55th Street, Suite 202, Boulder, CO 80301 (“Licensee”), each a “Party” and hereafter collectively referred to as the “Parties”.
EXCLUSIVE PATENT LICENSE AGREEMENTLicense Agreement • April 21st, 2020 • ArcherDX, Inc. • In vitro & in vivo diagnostic substances • Massachusetts
This License Agreement (“Agreement”) is made as of the July 23, 2013 (“Effective Date”), by and between Archer Dx, Inc., a Delaware corporation, having a principal place of business at 16042 W. 59th Ave., Golden, CO 80403 (“Company”) and The General Hospital Corporation, d/b/a Massachusetts General Hospital, a not-for-profit Massachusetts corporation, with a principal place of business at 55 Fruit Street, Boston, Massachusetts 02114 (“Hospital”), each referred to herein individually as a “Party” and collectively as the “Parties”.
OFFICE LEASEOffice Lease • April 21st, 2020 • ArcherDX, Inc. • In vitro & in vivo diagnostic substances • Washington
This Lease (this “Lease”) is made and entered into by and between REEF FLATIRON LLC, a Washington limited liability company (“Landlord”) and Enzymatics, Inc., a Massachusetts corporation (“Tenant”).
First Amendment to Exclusive Patent License Agreement A217008.04ArcherDX, Inc. • April 21st, 2020 • In vitro & in vivo diagnostic substances
This First Amendment (“First Amendment”) to the Exclusive Patent License Agreement MGH # A217008, (the “Agreement”), dated July 23, 2013 is made as of August 15, 2016 (“First Amendment Effective Date) by and between The General Hospital Corporation, d/b/a Massachusetts General Hospital, a not-for-profit Massachusetts corporation, with a principal place of business at 55 Fruit Street, Boston, Massachusetts 02114 and ArcherDx, Inc., a Delaware Corporation, having a principal place of business at 2477 55th St. # 202 Boulder, Colorado 80301.
